Immunopharmacogenomics: Mechanisms of HLA‐Associated Drug Reactions
- 17 July 2021
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 110 (3), 607-615
- https://doi.org/10.1002/cpt.2343
Abstract
The human leukocyte antigen (HLA) system is the most polymorphic in the human genome that has been associated with protection and predisposition to a broad array of infectious, autoimmune, and malignant diseases. More recently over the last two decades, HLA class I alleles have been strongly associated with T-cell mediated drug hypersensitivity reactions. In the case of abacavir hypersensitivity and HLA-B*57:01, the 100% negative predictive value and low number needed to test to prevent a single case has led to a durable and effective global pre-prescription screening strategy. However, HLA associations are still undefined for most drugs clinically-associated with different delayed drug hypersensitivity phenotypes, and an HLA association relevant to one population is not generalizable across ethnicities. Furthermore, while a specific risk HLA allele is necessary for drug-induced T-cell activation, it is not sufficient. The low and incomplete positive predictive value has hindered efforts at clinical implementation for many drugs, however, has provided the impetus to understand the mechanisms of HLA class I restricted T-cell mediated drug hypersensitivity reactions. Current research has focused on defining the contribution of additional elements of the adaptive immune response and other genetic and ecologic risk factors that contribute to drug hypersensitivity risk. In this review we focus on new insights into immunological, pharmacological, and genetic mechanisms underpinning HLA associated drug reactions and the implications for future translation into clinical care.Keywords
This publication has 25 references indexed in Scilit:
- Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse ReactionsJournal of Investigative Dermatology, 2015
- Abacavir-Reactive Memory T Cells Are Present in Drug Naïve IndividualsPLOS ONE, 2015
- Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysinAnnals Of The Rheumatic Diseases, 2014
- KIR3DS1/L1 and HLA-Bw4-80I are associated with HIV disease progression among HIV typical progressors and long-term nonprogressorsBMC Infectious Diseases, 2013
- Immune self-reactivity triggered by drug-modified HLA-peptide repertoireNature, 2012
- Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in TaiwanThe New England Journal of Medicine, 2011
- Mechanisms for T cell receptor triggeringNature Reviews Immunology, 2010
- CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysisJournal of Allergy and Clinical Immunology, 2010
- HLA-B*5701 Screening for Hypersensitivity to AbacavirThe New England Journal of Medicine, 2008
- Specificity pockets for the side chains of peptide antigens in HLA-Aw68Nature, 1989